Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (July 2021)
34 slides from Inoviq's investor presentation, Jul 23, 2021
Slide 1: Detecting cancer earlier to save lives
Detecting cancer earlier to save lives Capital Raising Investor Presentation 23 July 2021 BARD1 Presentation July 2021 Page 1
Slide 2: Important notice and disclaimer
Important notice and disclaimer The following notice and disclaimer applies to this investor presentation (Presentation or document) and you are therefore advised to read this carefully before While the Company believes that this non-IFRS/non-GAAP financial information provides useful information to
Slide 3: Executive summary
Executive summary Cancer diagnostics • Focused on early cancer detection to save lives company Game changing • Patented technologies with clear advantages for multiple cancer applications technology Compelling results • >95% sensitivity & 100% specificity for detection of breast and ovarian cancers
Slide 4: Company overview
Company overview BARD1 Life Sciences (ASX: BD1) BARD1 History • Diagnostics company focused on early cancer detection 2016 BARD1 AAb technology acquired • Game-changing technology with multiple applications 2020 SubB2M and EXO-NET® technologies acquired / in-licensed • Dx pipeline for breast, ovaria
Slide 5: Unmet need for early cancer detection
Unmet need for early cancer detection The problem 5-year survival rates by stage at diagnosis1 ▪ Screening tests often have high false-positives &/or insufficient sensitivity for early-stage cancer (I/II) 99% 100% 98% ▪ Cancer often detected at late-stage (III/IV) after symptoms 90% 93% have appeare
Slide 6: Diagnostics continuum
Diagnostics continuum Before diagnosis After diagnosis Prediction Screening Diagnosis Prognosis Monitoring Genetic tests to Imaging and blood Imaging and biopsy Genomic, tissue Imaging and blood predict the risk of tests for early tests for and blood tests for tests to monitor developing a detection
Slide 7: Products and pipeline
Products and pipeline Before diagnosis After diagnosis • Marketed products for bladder cancer 1 & exosome research • Lead pipeline products for breast & ovarian cancer Prediction Screening Diagnosis Prognosis Monitoring • Focused on cancer screening & monitoring ASSAY CLINICAL MARKETING NEXT PRODUCT
Slide 8: Global cancer diagnostics market
Global cancer diagnostics market Breast Cancer3 US$4.2b Mammography screening Pancreatic Cancer6 ▪ Global cancer burden: 50.6m people1 High self-exclusion & US$2.4b limited access No screening test ▪ 19.3m new cases and 10.0m deaths p.a.1 ▪ Global cancer diagnostics market worth US$250b2 ▪ BARD1 is
Slide 9: SubB2M technology
SubB2M™ | technology Game-changing technology for early detection and monitoring of cancer ▪ SubB2M is an engineered protein that specifically binds to ✓ POC results in breast and ovarian cancers show over 95% a unique sugar Neu5Gc sensitivity and 100% specificity across all cancer stages 3 ▪ Neu5Gc
Slide 10: SubB2M breast cancer test
SubB2M™| breast cancer test POC results show >95% sensitivity and 100% specificity for all BC stages Stage Breast Cancer Test • SubB2M-based ELISA for early detection and monitoring of BC n=118 (96 cancers : 22 controls) • POC study using SPR-based assay to evaluate detection of Neu5Gc in BC Sensiti
Slide 11: Market potential | US breast cancer screening
11 Market potential | US breast cancer screening ▪ World’s most common cancer (2.3m new cases & 685k deaths pa)1 ▪ US: 3.7m survivors, 234k new cases & 43k deaths pa1,2 ▪ Life-time risk of 12.9% 2 ▪ Screening using mammography recommended for average-risk women2 ▪ Issues with high false positives, s
Slide 12: SubB2M ovarian cancer test
SubB2M™| ovarian cancer test POC results show 100% sensitivity and 100% specificity for all OC stages Stage Ovarian Cancer Test • SubB2M-based ELISA for early detection and monitoring of OC n=69 (47 cancers : 22 controls) • POC study using SPR-based assay to evaluate detection of Neu5Gc in OC Sensit
Slide 13: Market potential | US ovarian cancer screening
13 Market potential | US ovarian cancer screening ▪ World’s deadliest gynaecological cancer (314k new cases & 207k deaths pa)1 ▪ US: 235k survivors, 24k new cases & 14k deaths pa1,2 ▪ Life-time risk of 1.2%, increases to 35-70% with BRCA1 mutation 2,4 ▪ Average 5-year survival 49% due to late-stage
Slide 14: SubB2M ELISA-based test method
SubB2M™ | ELISA-based test method ▪ Simple ELISA-based method used in high throughput AAA BBB commercial laboratories worldwide ▪ Developing pan-cancer SubB2M test (ELLBA) for monitoring cancer treatment response or recurrence ▪ Developing cancer-specific SubB2M tests (ELISA) for early detection of
Slide 15: SubB2M goals and strategy
SubB2M | goals and strategy GOAL is to develop and commercialise superior blood tests for early cancer detection and monitoring Develop • Complete assay development of SubB2M-based ELISA compatible with high-throughput SubB2M-based laboratory workflow (assay development) ELISA • Advance clinical tes
Slide 16: SubB2M activity timeline
SubB2M | activity timeline Calendar Year 2021 2022 2023 PARTNERS Research Assay Development CMO SubB2M Clinical Testing Breast Cancer Technical Validation Lab Partner test Clinical Validation Lab Partner LDT Market Launch Lab Partner Research Assay Development CMO SubB2M Clinical Testing Ovarian Can
Slide 17: Other research projects
Other research projects Additional research projects are being evaluated for other cancers and indications for use EXO-NET® technology projects BARD1 AAb technology projects • EXO-NET is a molecular NET technology for capture of exosomes • BARD1 technology detects autoantibodies to variant BARD1 pro
Slide 18: Products
Products Two products in-market for exosome research and detection of hTERT RUO EXO-NET Anti-hTERT (launched May 2021) Antibody • RUO EXO-NET is a research use only pan-exosome capture tool • hTERT test is an immunocytochemistry (ICC) assay that detects • Suitable for blood, urine, saliva and cell c
Slide 19: Catalysts and plans
Catalysts and plans Expected value-adding milestones over the next 12 months Key catalysts Other milestones 4Q• Feasibility CY2020results for SubB2M-ELISA tests (studies • Appoint distribution partner/s for RUO EXO-NET® commenced) • Expand co-development / licensing opportunities for • Clinical test
Slide 20: Capital raising overview
Capital raising overview ▪ The Company has raised A$15 million via a placement to sophisticated and professional investors (Placement): ▪ Approximately 9.7m new Shares to be issued under the Company’s placement capacity under ASX Listing Rules Placement 7.1 & 7.1A ▪ The Placement was not underwritte
Slide 21: Use of Funds
Use of Funds The funds raised under the Offer will be used to expand and advance BARD1’s clinical and commercialisation program and strengthen BARD1’s balance sheet. Uses A$m • Post completion of the capital raising BARD1 will have a pro Research & development – predominantly SubB2M tests for ovaria
Slide 22: Indicative Timetable
Indicative Timetable* Date Item Thursday, 22 July 2021 Record date for SPP Friday, 23 July 2021 Recommencement of trading Thursday, 29 July 2021 Settlement of placement Lodgement of Prospectus Friday, 30 July 2021 Issue of Placement Shares Dispatch of Prospectus for SPP and Options Offers Wednesday,
Slide 23: Contacts
Contacts BARD1 Life Sciences Ltd 23 Normanby Road Notting Hill VIC 3168 Australia P +61 3 9548 7586 E info@bard1.com W www.bard1.com Dr Leearne Hinch | CEO E leearne@bard1.com M +61 400414416 BARD1 Presentation July 2021 Page 23
Slide 24: Appendices
Appendices BARD1 Presentation July 2021 Page 24
Slide 25: Healthcare experienced board
Healthcare experienced board DR GEOFF CUMMING PhD MAX JOHNSTON PHILIP POWELL Prof ALLAN CRIPPS AO PhD Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director • Healthcare and biotechnology • Healthcare industry director and • Healthcare industry director and • Dis
Slide 26: Management with biotech track record
Management with biotech track record DR LEEARNE HINCH DR PETER FRENCH PhD DR WAYNE JENSEN PhD DR EMILY STEIN PhD TONY DI PIETRO Chief Executive Officer Chief Scientific Officer R&D Director R&D Manager (USA) CFO & Company Secretary • Dr Leearne Hinch BSc BVMS • Dr Peter French BSc MSc PhD • Dr Wayne
Slide 27: Strong patent portfolio
Strong patent Patent Family SubB2M Title Granted Pending Expiry portfolio PCT/AU2017/051230 (WO 2018/085888) Subtilase cytotoxin B subunit mutant AU, BR, CA, CN, EP, IN, JP, KR, US 2037 APPA/2021901444 Methods of analysing a sample 2042 BARD1 PCT/FR01/02731 Truncated BARD1 protein, and its diagnosti
Slide 28: Key risks
Key risks This section includes details of the key risks attaching to an investment in BARD1 securities. These risks may affect the future operating and financial performance of BARD1 and the value of BARD1 securities. Before deciding whether to invest in BARD1securities, you should consider whether
Slide 29: Key risks (cont.)
Key risks (cont.) SPECIFIC RISK DESCRIPTION It is likely that BARD1 will need to form marketing and/or product development alliances with third parties for BARD1 products in countries which BARD1 seeks to commercialise (subject to ongoing legal and regulatory compliance and Commercialisation financi
Slide 30: Key risks (cont.)
Key risks (cont.) SPECIFIC RISK DESCRIPTION Reliance on key BARD1 currently employs, or engages as consultants, a number of key management and scientific personnel and seeks to engage further personnel. The failure to recruit new personnel, or the loss of any existing personnel could materially and
Slide 31: Key risks (cont.)
Key risks (cont.) SPECIFIC RISK DESCRIPTION Price of BARD1 There are general risks associated with investments in equity capital such as BARD1 securities. The trading price of BARD1 securities may fluctuate with movements in equity capital markets in Australia and internationally. There is no assura
Slide 32: Key risks (cont.)
Key risks (cont.) SPECIFIC RISK DESCRIPTION Ukrainian gold As has been previously announced by BARD1, on 10 July 2007, BARD1's group disposed of its Ukrainian gold mining assets for US$5,000,000. US$3,000,000 of this amount remains outstanding and will only be received after the purchaser meets a re
Slide 33: Key risks (cont.)
Key risks (cont.) GENERAL RISK DESCRIPTION Liquidity BARD1 securities are only listed on the securities exchange operated by ASX and will not be listed for trading on any other financial markets, other than Chi-X. There can be no guarantee that an active market in BARD1 securities will continue. If
Slide 34: Key risks (cont.)
Key risks (cont.) GENERAL RISK DESCRIPTION COVID-19 The current global COVID-19 pandemic may continue to impact existing product revenues for hTERT and may impact the BARD1’s early-stage research projects or development programs. Many clinical laboratories have shifted focus to COVID-19 testing rath